Rab25 is responsible for phosphoinositide 3-kinase/AKT-mediated cisplatin resistance in human epithelial ovarian cancer cells

Molecular Medicine Reports

Volumn 11, Issue 3, 2015, Pages 2173-2178

  Fan, Yang ^a   Wang, Long ^b   Han, Xuechuan ^a   Liu, Xueqin ^a   Ma, Hongyun ^a  

^a Ningxia Eye Hospital   (China)

^b NINGXIA MEDICAL UNIVERSITY   (China)

Author keywords

Cisplatin resistance; Ovarian cancer; Phosphoinositide 3 kinase AKT pathway; Rab25

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BETA ACTIN; CISPLATIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAB PROTEIN; RAB25 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; RAB25 PROTEIN, HUMAN; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HUMAN; HUMAN CELL; OVARIAN CANCER CELL LINE; OVARY CARCINOMA; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; DRUG EFFECTS; DRUG RESISTANCE; GENE SILENCING; GENETICS; METABOLISM; NEOPLASM; OVARY TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RAB GTP-BINDING PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84916633576     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2963     Document Type: Article

References (22)

1. Kim A, Ueda Y, Naka T and Enomoto T: Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res 31: 14, 2012.
2. Colombo N, Van Gorp T, Parma G, et al: Ovarian cancer. Crit Rev Oncol Hematol 60: 159-179, 2006.
3. Wrzeszczynski KO, Varadan V, Byrnes J, et al: Identification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancer. PloS One 6: e28503, 2011.
4. Holschneider CH and Berek JS: Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 19: 3-10, 2000.
5. Shih Ie M and Davidson B: Pathogenesis of ovarian cancer: clues from selected overexpressed genes. Future Oncol 5: 1641-1657, 2009.
6. Nelson AE, Francis JE and Zorbas H: Population screening and early detection of ovarian cancer in asymptomatic women. Aust NZ J Obstet Gynaecol 49: 448-450, 2009.
7. Trimbos JB, Parmar M, Vergote I, et al; International Collaborative Ovarian Neoplasm 1 and the European Organisation for Research and Treatment of Cancer Collaborators-Adjuvant Chemotherapy in Ovarian Neoplasm. International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 95: 105-112, 2003.
8. Aabo K, Adams M, Adnitt P, et al: Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced ovarian cancer trialists' group. Br J Cancer 78: 1479-1487, 1998.
9. Markman M: Optimizing primary chemotherapy in ovarian cancer. Hematol Oncol Clin North Am 17: 957-968, 2003.
10. Ali AY, Farrand L, Kim JY, et al: Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum. Ann NY Acad Sci 1271: 58-67, 2012.
11. Mitra S, Cheng KW and Mills GB: Rab25 in cancer: a brief update. Biochem Soc Trans 40: 1404-1408, 2012.
12. Agarwal R, Jurisica I, Mills GB and Cheng KW: The emerging role of the RAB25 small GTPase in cancer. Traffic 10: 1561-1568, 2009.
13. Cheng KW, Lahad JP, Kuo WL, et al: The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med 10: 1251-1256, 2004.
14. Caswell PT, Spence HJ, Parsons M, et al: Rab25 associates with alpha5beta1 integrin to promote invasive migration in 3D microenvironments. Dev Cell 13: 496-510, 2007.
15. Liu Y, Tao X, Jia L, et al: Knockdown of RAB25 promotes autophagy and inhibits cell growth in ovarian cancer cells. Mol Med Rep 6: 1006-1012, 2012.
16. Fan Y, Xin XY, Chen BL and Ma X: Knockdown of RAB25 expression by RNAi inhibits growth of human epithelial ovarian cancer cells in vitro and in vivo. Pathology 38: 561-567, 2006.
17. Wang H, Li H, Zuo M, et al: Lx2-32c, a novel taxane and its antitumor activities in vitro and in vivo. Cancer Lett 268: 89-97, 2008.
18. Goldenring JR and Nam KT: Rab25 as a tumour suppressor in colon carcinogenesis. Br J Cancer 104: 33-36, 2011.
19. Cheng KW, Lahad JP, Gray JW and Mills GB: Emerging role of RAB GTPases in cancer and human disease. Cancer Res 65: 2516-2519, 2005.
20. Casanova JE, Wang X, Kumar R, et al: Association of Rab25 and Rab11a with the apical recycling system of polarized Madin-Darby canine kidney cells. Mol Biol Cell 10: 47-61, 1999.
21. Wang X, Kumar R, Navarre J, Casanova JE and Goldenring JR: Regulation of vesicle trafficking in madin-darby canine kidney cells by Rab11a and Rab25. J Biol Chem 275: 29138-29146, 2000.
22. Fraser M, Leung B, Jahani-Asl A, Yan X, Thompson WE and Tsang BK: Chemoresistance in human ovarian cancer: the role of apoptotic regulators. Reprod Biol Endocrinol 1: 66, 2003.